BEKhealth uses AI to address the historical underrepresentation of women in clinical trials
March is Women’s History Month, a time to celebrate the contributions of women throughout history and acknowledge the challenges they have faced. One area where women have been historically underserved is in the clinical trial space. Clinical trials are essential for testing new treatments, but historically, women have been underrepresented in medical research, which has led to significant gaps in our understanding of how certain treatments affect women.
Fortunately, there are organizations working to address this issue and improve healthcare outcomes for women. BEKhealth, an AI-powered patient-matching software company, who’s mission is to enhance human health and well-being by significantly increasing patient access to clinical research is one such organization.
By using the BEKhealth platform, healthcare providers can quickly identify matching patients for clinical trials and other healthcare initiatives. The platform can be filtered by various demographics, including race, ethnicity, and gender, allowing providers to connect with all patients and ensure that they are being adequately represented in clinical trials and other healthcare initiatives.
This is particularly important for women, who have historically been underrepresented in clinical trials. According to the Office of Research on Women’s Health, only 19% of clinical trial participants for cardiovascular disease are women, which is troublesome when the leading cause of death in women is, in fact, cardiovascular disease. This is despite the fact that women have different symptoms and risk factors for cardiovascular disease than men, highlighting the importance of including women in clinical trials to ensure that treatments are effective for both genders.
BEKhealth’s platform can help healthcare providers address this issue by allowing them to quickly identify and connect with potential female participants for clinical trials and other healthcare initiatives. By doing so, healthcare providers can help ensure that women are adequately represented in healthcare research and receive treatments that are tailored to their unique needs.
As we draw Women’s History Month to a close, BEKhealth is proud to partner with healthcare providers to improve outcomes and ensure innovative therapies are safe and effective for all patients through clinical trials, including women. We recognize that there is still much work to be done to ensure that all patients, regardless of their background or identity, have access to equitable clinical trials, and we remain committed to driving change in the industry. By continuing to prioritize diversity and inclusion in our platform and our partnerships, we hope to make a positive impact on the healthcare landscape for years to come.
Read More
Beyond Recruitment: Leveraging RWD to Power a Continuous Clinical Trial Ecosystem
Beyond Recruitment: Leveraging RWD to Power a Continuous Clinical Trial Ecosystem Clinical trials have long been organized in stages: protocol drafting, site selection, recruitment, data collection, analysis, and follow-up. As real-world data (RWD) and real-world...
AI + Real-World Data: Accelerating What’s Possible in Clinical Research
AI + Real-World Data: Accelerating What’s Possible in Clinical Research Healthcare generates more data today than at any point in history. Yet despite billions of data points created daily, much of it remains fragmented, underutilized, and locked away in formats too...
Protocol Deviations and Patient Mismatch: The Silent Threat to Trial Success
Protocol Deviations and Patient Mismatch: The Silent Threat to Trial Success Clinical trials are already under immense pressure—budgets are tight, timelines are slipping, and staff bandwidth is shrinking. Yet one of the most overlooked threats to trial success isn’t a...
Top 5 Clinical Trial Enrollment Metrics to Watch in 2026
Top 5 Clinical Trial Enrollment Metrics to Watch in 2026 Why 2026 Will Redefine Clinical Trial Enrollment Clinical trial enrollment is entering a new era. As we move into 2026, sponsors, regulators, and patients expect more than just filled studies—they demand speed,...